Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.

Clinical and translational medicine - 1 Feb 2023

Cunningham Richard, Jia Siyang, Purohit Krishna, Salem Omar, Hui Ning Sze, Lin Yue, Carragher Neil O, Hansen Carsten Gram

Abstract excerpt

The Hippo signalling pathway is dysregulated across a wide range of cancer types and, although driver mutations that directly affect the core Hippo components are rare, a handful is found within pleural mesothelioma (PM). PM is a deadly disease of the lining of the lung caused by asbestos exposure. By pooling the largest-scale clinical datasets publicly available, we here interrogate associations between the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hippo Signaling Pathway
Share to Mesothelioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Serine-Threonine Kinases

Share to Transcription Factors

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36740402
DOI: 10.1002/ctm2.1190
PMCID: PMC9899629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.PMID 36740402Read ↗

Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma.Semantic proximity Read ↗

Development of a pipeline to evaluate YAP-TEAD inhibitor potential <i>-</i> direct TEAD inhibition represses cancerous growth in a <i>NF2</i> -mutant model of mesotheliomaSemantic proximity Read ↗

Genomics and Epigenetics of Malignant MesotheliomaSemantic proximity Read ↗

Progress and challenges in Mesothelioma: From bench to bedside.Semantic proximity Read ↗

Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferationSemantic proximity Read ↗

Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.Semantic proximity Read ↗

Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathwaysSemantic proximity Read ↗

How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing and somatic mutationsSemantic proximity Read ↗

Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status.Semantic proximity Read ↗

The Hippo Pathway as a Driver of Select Human Cancers.Semantic proximity Read ↗

A molecular phenotypic map of Malignant Pleural MesotheliomaSemantic proximity Read ↗

Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.